DASATINIB IN CHRONIC MYELOID LEUKEMIA
Abstract
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosomepositive CML (chronic myeloid leukemia), but relaps occurs, mainly as a reults of the outgrowth of leukemic subclones with imatinib resistant BCR-ABL mutation.Some patientswith various phases of CML note tolerate imatinib. Dasatinib is an orally available ABLkinase inhibitor that differs from imatinib in that it can bind to both the active andinactive conformation of the ABL kinase domain.The oral inhibitor tirozin kinazedasatinib was approved in 2006 for use in patients with CML who are unable to tolerate orhave not responder to other treatments.Patients We treated 2 patients in chronic phase CML who dident tolerate imatinib (400 mg per day)and one patient in accelerated phase CML (imatinib 800 mg per day) withdasatinib.Dasatinib was administered orally (50 to 140 mg per day) once or twice daily. Hematologic and cytogenetic responses were seen in 2 patients. Myelosuppression was commonbut not dose – limiting. One patients in chronic phase CML didnt tolerate also dasatinib.He had rush, nausea and vomiting. CONCLUSIONS Dasatinib induces hematologic and cytogenetic responses in patients with CML whocannot tolerate or are resistant to imatinib. Dasatinib has shown clinical benefit andtolerability in patients in all phases of CMLDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.